Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Change in Accured Expenses (2019 - 2025)

Pulmonx (LUNG) has disclosed Change in Accured Expenses for 7 consecutive years, with $528000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 27.87% to $528000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 million, a 269.71% increase, with the full-year FY2024 number at $462000.0, down 85.45% from a year prior.
  • Change in Accured Expenses was $528000.0 for Q3 2025 at Pulmonx, down from $2.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.0 million in Q4 2024 to a low of -$6.0 million in Q1 2024.
  • A 5-year average of $355315.8 and a median of $1.0 million in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 237.32% in 2021, then crashed 357.53% in 2022.
  • Pulmonx's Change in Accured Expenses stood at $1.5 million in 2021, then surged by 58.05% to $2.4 million in 2022, then decreased by 5.53% to $2.3 million in 2023, then surged by 76.48% to $4.0 million in 2024, then tumbled by 86.72% to $528000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Change in Accured Expenses are $528000.0 (Q3 2025), $2.5 million (Q2 2025), and -$4.9 million (Q1 2025).